Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Drugs Might Get Hit by SWIFT Ban on Russia Even If Exempted from Trade Sanctions
March 1, 2022
- Ozempic Shipment Suspension Expected from March: Novo
March 1, 2022
- Ono Sues AstraZeneca over PD-L1 Patent, Seeks 32 Billion Yen in Damage
March 1, 2022
- Shionogi, Ube Tie Up on Anti-RSV Drug, Eye Clinical Trial Launch in FY2023
March 1, 2022
- Mitsubishi Tanabe Snaps Up Seed Compounds through Research Collaboration with Chinese Biotech
February 28, 2022
- Number of Flu Patients Plunges to 1/1,200th of Pre-COVID Levels: Survey
February 28, 2022
- Horizon Launches Japan PIII for Thyroid Eye Disease Drug
February 25, 2022
- Fuji Pharma In-Licenses Sixth Biosimilar from Alvotech
February 25, 2022
- Shionogi Files COVID-19 Pill in Japan, Seeks Conditional Approval
February 25, 2022
- Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
- Medicago’s COVID-19 Vaccine Approved in Canada
February 25, 2022
- Enhertu Hits PFS, OS Goals in HER2 Low Breast Cancer
February 22, 2022
- BTK Inhibitor Velexbru Approved in Taiwan: Ono
February 22, 2022
- Novo Prepping for Listing of Ozempic 2 mg Version amid Supply Curbs
February 22, 2022
- Bayer Gets Eylea Biosame Approval in Japan as It Braces for Biosimilar Debuts
February 22, 2022
- UCB Japan Recalls Antiepileptic Med E Keppra IV
February 22, 2022
- Sleep Inducer Recalls by Fuji Yakuhin, Tatsumi Kagaku Tied to Tokyo Wholesaler’s Fake API Case
February 21, 2022
- BMS Japan to Kick Off Workplace Booster Program in March
February 18, 2022
- Parmodia-Deberza Combo Improves NASH in Mice: Kowa/Univ. of Tokyo
February 18, 2022
- AstraZeneca to Discontinue Bydureon, Zestril amid Weak Sales
February 18, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…